SG11202107396RA - Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers - Google Patents

Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Info

Publication number
SG11202107396RA
SG11202107396RA SG11202107396RA SG11202107396RA SG11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA SG 11202107396R A SG11202107396R A SG 11202107396RA
Authority
SG
Singapore
Prior art keywords
antibodies
solid tumor
advanced stage
stage solid
tumor cancers
Prior art date
Application number
SG11202107396RA
Other languages
English (en)
Inventor
Serena Masciari
Semra Yoruk
Karl Hsu
Nicolas Acquavella
Marie Bernardo
Robert Jabulowsky
Ugur Sahin
Friederike Gieseke
Trnkova Zuzana Jirakova
Timothy R Wagenaar
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11202107396RA publication Critical patent/SG11202107396RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202107396RA 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers SG11202107396RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962794896P 2019-01-21 2019-01-21
US201962926379P 2019-10-25 2019-10-25
EP19306471 2019-11-14
PCT/US2020/014039 WO2020154189A1 (fr) 2019-01-21 2020-01-17 Arn thérapeutique et anticorps anti-pd1 pour des cancers à tumeurs solides de stade avancé

Publications (1)

Publication Number Publication Date
SG11202107396RA true SG11202107396RA (en) 2021-08-30

Family

ID=69582159

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107396RA SG11202107396RA (en) 2019-01-21 2020-01-17 Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers

Country Status (13)

Country Link
US (1) US20220288199A1 (fr)
EP (1) EP3914355A1 (fr)
JP (1) JP2022518236A (fr)
KR (1) KR20210118870A (fr)
CN (1) CN113507963A (fr)
AU (1) AU2020210614A1 (fr)
BR (1) BR112021013965A2 (fr)
CA (1) CA3126110A1 (fr)
IL (1) IL284645A (fr)
MX (1) MX2021008605A (fr)
SG (1) SG11202107396RA (fr)
TW (1) TW202043274A (fr)
WO (1) WO2020154189A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6949131B2 (ja) 2017-02-28 2021-10-13 サノフイＳａｎｏｆｉ 治療用ｒｎａ
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
JP2022518235A (ja) * 2019-01-21 2022-03-14 サノフイ 進行期固形腫瘍がんの治療用ｒｎａ
IL300975A (en) * 2020-09-03 2023-04-01 Regeneron Pharma Methods for treating cancer pain by administering a PD-1 inhibitor
JP2023550880A (ja) * 2020-10-26 2023-12-06 サイチューン ファーマ 非黒色腫皮膚癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト
CA3195627A1 (fr) * 2020-10-26 2022-05-05 Stefano FERRARA Agoniste il-2/il-15r.beta..gamma. pour traiter le carcinome malpighien
CA3220882A1 (fr) * 2021-07-02 2023-01-05 David Scott Johnson Proteines de liaison anti-ctla-4 et leurs methodes d'utilisation
CN115260264B (zh) * 2022-02-28 2023-06-09 广州市恒诺康医药科技有限公司 用于rna加帽的化合物及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
SI2350129T1 (sl) 2008-08-25 2015-11-30 Amplimmune, Inc. Sestavki PD-1 antagonistov in postopek njihove uporabe
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
US9815897B2 (en) 2013-05-02 2017-11-14 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CA3080200A1 (fr) 2013-09-13 2015-03-19 Beigene Switzerland Gmbh Anticorps anti-pd1 et leur utilisation comme produits therapeutiques et produits de diagnostic
CA2932966C (fr) 2013-12-12 2022-03-22 Shanghai Hengrui Pharmaceutical Co., Ltd. Anticorps anti-pd-1, son fragment de liaison a l'antigene, et son application medicale
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2016005004A1 (fr) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilisation de séquences d'adn codant pour une séquence poly (a)
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
EP3344656A1 (fr) 2015-09-01 2018-07-11 Agenus Inc. Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
EA201891093A1 (ru) 2015-11-03 2018-10-31 Янссен Байотек, Инк. Антитела, специфически связывающие pd-1, и их применение
WO2018033254A2 (fr) * 2016-08-19 2018-02-22 Curevac Ag Arn pour la cancérothérapie
JP6949131B2 (ja) * 2017-02-28 2021-10-13 サノフイＳａｎｏｆｉ 治療用ｒｎａ

Also Published As

Publication number Publication date
TW202043274A (zh) 2020-12-01
BR112021013965A2 (pt) 2021-09-21
JP2022518236A (ja) 2022-03-14
KR20210118870A (ko) 2021-10-01
MX2021008605A (es) 2021-10-26
AU2020210614A1 (en) 2021-08-26
US20220288199A1 (en) 2022-09-15
EP3914355A1 (fr) 2021-12-01
WO2020154189A1 (fr) 2020-07-30
IL284645A (en) 2021-08-31
CA3126110A1 (fr) 2020-07-30
CN113507963A (zh) 2021-10-15

Similar Documents

Publication Publication Date Title
IL284645A (en) Therapeutic RNA and Anti PD1 antibodies for the treatment of solid cancer tumors in advanced stages
EP3891294A4 (fr) Méthodes de traitement du cancer de la prostate résistant à la castration et sensible à la castration
EP3999548A4 (fr) Anticorps dirigés contre la claudine 18 et méthodes de traitement du cancer
IL276446A (en) Methods for the selection and design of safer and more effective antibodies against CTLA-4 for cancer treatment
IL281441B (en) Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
PL3512882T3 (pl) Przeciwciała anty-c-met i ich koniugaty przeciwciał z lekami do efektywnej inhibicji nowotworów
IL277861A (en) Axl-specific antibodies for cancer treatment
ZA202106392B (en) Therapeutic rna for prostate cancer
IL288086A (en) Methods and materials for cancer treatment
EP3775167A4 (fr) Procédés de traitement du cancer à l'aide de lymphocytes t spécifiques d'un antigène tumoral
IL287554A (en) Rana is therapeutic for ovarian cancer
EP3713576A4 (fr) Méthodes de traitement du cancer
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
SG11202109514VA (en) Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy
IL289335A (en) New cancer antigens and methods
IL289334A (en) New cancer antigens and methods
IL289200A (en) New cancer antigens and methods
IL289205A (en) New cancer antigens and methods
EP4072580A4 (fr) Vaccin tumoral personnalisé et son utilisation pour l'immunothérapie du cancer
EP4007640A4 (fr) Polythérapie anticancéreuse d'anticorps anti-galectine-9 et d'agents chimiothérapeutiques
IL284646A (en) Therapeutic RNA for the treatment of solid cancer tumors in advanced stages
EP3691694A4 (fr) Anticorps monoclonaux d'adn ciblant le ctla-4 pour le traitement et la prévention du cancer
EP4081644A4 (fr) Procédés et agents de traitement de cancers à tumeurs solides
EP3947472A4 (fr) Anticorps thérapeutiques pour le traitement du cancer du poumon
EP4077677A4 (fr) Nanoparticule d'arn pour le traitement du cancer du foie